Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Multiple Sclerosis

  Free Subscription


1 Ann Neurol
1 Arch Phys Med Rehabil
1 Eur Neurol
2 J Immunol
1 J Neurol Neurosurg Psychiatry
1 J Neurosci
2 Mult Scler
1 Nat Rev Neurol
1 Neurologia
4 Neurology

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Neurol

  1. FISSOLO N, Pignolet B, Matute-Blanch C, Trivino JC, et al
    MMP9 is decreased in natalizumab-treated MS patients at risk for PML.
    Ann Neurol. 2017 Jul 6. doi: 10.1002/ana.24987.
    PubMed     Text format     Abstract available

    Arch Phys Med Rehabil

  2. GOVEROVER Y, Chiaravalloti ND, O'Brien A, DeLuca J, et al
    Evidenced Based Cognitive Rehabilitation for Persons with Multiple Sclerosis: An Updated Review of the Literature from 2007-2016.
    Arch Phys Med Rehabil. 2017 Sep 25. pii: S0003-9993(17)31117.
    PubMed     Text format     Abstract available

    Eur Neurol

  3. VILLAVERDE-GONZALEZ R, Gracia Gil J, Perez Sempere A, Millan Pascual J, et al
    Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.
    Eur Neurol. 2017;77.
    PubMed     Text format     Abstract available

    J Immunol

  4. SEKI SM, Stevenson M, Rosen AM, Arandjelovic S, et al
    Lineage-Specific Metabolic Properties and Vulnerabilities of T Cells in the Demyelinating Central Nervous System.
    J Immunol. 2017;198:4607-4617.
    PubMed     Text format     Abstract available

  5. GIBSON SA, Yang W, Yan Z, Liu Y, et al
    Protein Kinase CK2 Controls the Fate between Th17 Cell and Regulatory T Cell Differentiation.
    J Immunol. 2017;198:4244-4254.
    PubMed     Text format     Abstract available

    J Neurol Neurosurg Psychiatry

  6. GAJOFATTO A, Nourbakhsh B, Benedetti MD, Waubant E, et al
    Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Sep 22. pii: jnnp-2017-316911.
    PubMed     Text format    

    J Neurosci

  7. FELIU A, Bonilla Del Rio I, Carrillo-Salinas FJ, Hernandez-Torres G, et al
    2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.
    J Neurosci. 2017;37:8385-8398.
    PubMed     Text format     Abstract available

    Mult Scler

  8. CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
    Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
    Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
    PubMed     Text format     Abstract available

  9. MOSS-MORRIS R, Norton S
    Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
    Mult Scler. 2017;23:1436-1440.
    PubMed     Text format    

    Nat Rev Neurol

    Multiple sclerosis: A possible link between multiple sclerosis and gut microbiota.
    Nat Rev Neurol. 2017 Sep 29. doi: 10.1038/nrneurol.2017.
    PubMed     Text format    


    The role of astrocytes in multiple sclerosis pathogenesis.
    Neurologia. 2017 Sep 25. pii: S0213-4853(17)30281.
    PubMed     Text format     Abstract available


    Multiple sclerosis, inflammation in the brain, and mood.
    Neurology. 2017;89:e169-e171.
    PubMed     Text format    

  13. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1429-1430.
    PubMed     Text format    

  14. SETHI NK
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis and Physician-assisted death in chronic neurologic diseases.
    Neurology. 2017;89:1429.
    PubMed     Text format    

    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1428.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.